Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

Sponsor
Ruijin Hospital
Study ID
NCT05201326
Phase
PHASE1
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher level of clinical evidence-based evidence for the clinical treatment of recurrent GBM, and fill the guidelines for the treatment of recurrent GBM.

Key Dates

Start date
Dec 22, 2021
Status verified
Jan 2022
Primary completion
Dec 20, 2022
Completion
Dec 20, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm
    irinotecan + bevacizumab + Re-radiotherapy

Primary Outcome Measure

serious adverse events (SAE) [ Time Frame: From baseline to 28 days after the end of treatment ]

Central Contacts

Related Studies